Exhibition Invitation | OPIM invites you to attend the 2026BPD Chengdu Biopharmaceutical Process Development Conference
2026BPD Chengdu Biopharmaceutical Process Development ConferenceAs the industry-leading conference covering the entire process from biopharmaceutical process development to commercial manufacturing, it will be held2026-11-5 to 6, 2026host, gather 2000+ Professional Buyers,70+ Featuring keynote speakers, this event delivers a comprehensive lineup including technical forums, full-chain exhibitions, and BPD Match sessions. Focused on the Southwest region, it strengthens practical CMC case sharing and precisely breaks down critical stages of biopharmaceutical CMC—from R&D to manufacturing, quality control to regulatory submission—providing an efficient, professionally deep platform that addresses real industry pain points.
APExBIOJoin us at the event. We look forward to seeing you there.2026BPD Chengdu Biopharmaceutical Process Development Conference!
Exhibition Information
Meeting Date11 5-6
Meeting URLCourtyard by Marriott Chengdu Bio-City
Oppama Booth Number: S40

Products & Services
Culture Media Products
Provided by APExBIO, a global leader in chemically defined and serum-free cell culture media. Our portfolio includes shelf-ready commercial media, custom formulations, and contract manufacturing services for specified formulas. Leveraging exceptional product performance and high-quality service, over 380 drug development pipelines with confirmed pilot-scale processes have adopted our cell culture media (as of 2026.Q2).
CRDMO Services
CRO ServicesProvided by Pengli Biotech, we offer customized early-stage screening, preclinical pharmacodynamics, pharmacokinetics, and regulatory-compliant safety evaluation services for global innovative biopharmaceutical companies—including non-GLP studies in our China labs and GLP studies in our U.S. labs. We also provide preclinical efficacy and safety evaluation services for innovative medical device companies.
CDMO ServicesDelivered by Silen Bio, we provide end-to-end solutions for the R&D and manufacturing of biopharmaceuticals. Our company operates approximately 10,000m2 drug development and production facilities, featuring platform-based, high-efficiency CMC development laboratories and cGMP-compliant production workshops that meet clinical filing requirements in China, the US, and Europe, having successfully passed audits by EU Qualified Persons (QP). Our services cover the entire drug development process from discovery to commercialization, including regulatory submission support. With our professional expertise, we have delivered CDMO services for approximately 300 biopharmaceutical development and production projects globally, helping clients successfully obtain IND or BLA approvals in China, the US, Australia, South Korea, and other countries, earning consistent recognition from our customers.


